Puma Biotechnology | PBYI - Passivo Circulante





Passivo Circulante Alterar Data
Agios Pharmaceuticals USD 77.59M 7.37M 2026-09
Alnylam Pharmaceuticals USD 2.06B 550.49M 2026-09
Amgen USD 23.23B 2.27B 2026-09
Biogen USD 3.9B 18.7M 2026-09
BioMarin Pharmaceutical USD 1.6B 59.17M 2026-09
Daiichi Sankyo JPY 882.78B 117.08B 2026-09
Exelixis USD 411.88M 49.95M 2026-09
Gilead Sciences USD 12B 982M 2026-09
Glaxosmithkline GBP 20.72B 1.71B 2026-09
Incyte USD 1.44B 125.72M 2026-09
MacroGenics USD 108.82M 12.88M 2026-06
Moderna USD 2.53B 139M 2026-06
Novartis USD 32.52B 777M 2026-09
Pfizer USD 31.73B 920M 2026-09
PTC Therapeutics USD 776.08M 5.01M 2026-09
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 6.2B 671.5M 2026-09
Roche Holding CHF 28.85B 846M 2026-06
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
Takeda JPY 2.6T 161B 2026-09
TG Therapeutics USD 268.49M 81.38M 2026-06
Ultragenyx Pharmaceutical USD 389M 38M 2026-09
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Vertex Pharmaceuticals USD 5B 1.06B 2026-09